Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain, Postoperative 4 Breast Neoplasms 3 Pain 2 Lung Neoplasms 2 Uterine Cervical Dysplasia 1 Thyroid Neoplasms 1 Supratentorial Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Postoperative Hemorrhage 1 Nerve Block 1 Musculoskeletal Diseases 1 Mouth Neoplasms 1 Malignant Neoplasms of Male Genital Organs 1 Hypotension 1 Head and Neck Neoplasms 1 Goiter 1 Chronic Pain 1 Carcinoma, Renal Cell 1 Bowen's Disease 1 Agnosia 1 Acute Upper Gastrointestinal Bleeding 1 Acute Pain 1

Interventions

Iodine-131 14 trametinib 9 dabrafenib 9 Thyroidectomy 9 Surgical Procedures, Operative 9 lenvatinib 8 Thyroxine 8 Magnetic Resonance Spectroscopy 8 pembrolizumab 7 Paclitaxel 7 anlotinib 6 Thyrotropin Alfa 6 selpercatinib 5 Sorafenib 5 Saline Solution 5 Radiofrequency Ablation 5 Everolimus 5 pazopanib 4 Vemurafenib 4 Sunitinib 4 Radiotherapy 4 Nivolumab 4 Fluorodeoxyglucose F18 4 Dexmedetomidine 4 Cyclophosphamide 4 Biopsy, Fine-Needle 4 Biopsy 4 Bevacizumab 4 apatinib 3 Triiodothyronine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thyroid Neoplasms × Epinephrine × Clear all

NCT02112370 2017-08-04

REBT

Seoul National University Hospital

Phase 3 Completed

148 enrolled 17 charts

Goiter, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡